

FSMA



FINANCIAL SERVICES AND
MARKETS AUTHORITY

Transparency notification Form TR-1 BE Help

How to use this form?

TR-1 BE is an interactive form.

Therefore it is essential that you [download it again for each new notification](#).

You can select the name of an issuer in the list referred to in Section 2.

The form consists of two parts: [Part I](#), that has to be transmitted to both the FSMA and the issuer, and [Part II](#), to be sent exclusively to the FSMA.

Once you have opened the form on the FSMA's website, start by [saving](#) it on your computer (using "save as") before filling it in. When opening the file, remember also to verify that [macros](#) are active.

In order to [add rows](#) in the various sections of Part I (e.g. if there are several notifiers), please use the "+" and "-" buttons.

The names of the persons subject to a notification requirement as indicated in Part I automatically appear in Part II when you click on the ["PART II"](#) button in Section 6. It is not possible to add any additional rows in Part II.

Please [do not unprotect](#) the form; please fill in only where authorized and [do not modify](#) the formulas.

In Section 10, start with groups. In the case of [groups](#) of notifiers with subtotals to be filled in, please identify the members of the group and subsequently [click](#) on " Σ " to fill in a subtotal. Repeat this for each group. Finish with people notifying alone.

Once Section 10 is completed, [click](#) on "[CALCULATE](#)" to show the totals and subtotals.

For further details, please refer to the extract from the Guide to the Transparency Legislation.

The (unsigned) form should be transmitted in [xlsm](#) format. In addition, a signed copy should be transmitted in [PDF](#) format.

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Passive crossing of a threshold, downward crossing of the lowest threshold

4) Notification by

A parent undertaking or a controlling person

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Novartis AG	Lichtstrasse 35, 4056 Basel, Switzerland
Novartis Pharma AG	Lichtstrasse 35, 4056 Basel, Switzerland

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

28/10/2022 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

77,825,765

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Novartis AG	0	0		0.00%	
Novartis Pharma AG	2,177,226	2,177,226		2.80%	
Subtotal	2,177,226	2,177,226		2.80%	
TOTAL		2,177,226	0	2.80%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
					0	0.00%	
TOTAL					0	0.00%	

 **The totals** will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	2,177,226	2.80%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Novartis Pharma AG is a wholly-owned direct subsidiary of Novartis AG.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

Done at

On (DD/MM/YYYY)

Name & capacity

Signature
 Signature

FSMA

FINANCIAL SERVICES AND
MARKETS AUTHORITY**Transparency notification**
Form TR-1 BE
PART II**Persons subject to the notification requirement**

<u>Name</u>	<u>Address</u>	<u>Phone number</u>	<u>E-mail</u>	<u>Contact person (for legal entities)</u>
Novartis AG	Lichtstrasse 35, 4056 Basel, Switzerland	41613245365	marc.ceulemans@novartis	Marc Ceulemans
Novartis Pharma AG	Lichtstrasse 35, 4056 Basel, Switzerland	41613245365	marc.ceulemans@novartis	Marc Ceulemans

Mandatory

<u>Name</u>	<u>Address</u>	<u>Phone number</u>	<u>E-mail</u>	<u>Contact person (for legal entities)</u>

Invoicing data

<u>Name</u>	<u>Address</u>	<u>Phone number</u>	<u>E-mail</u>	<u>Contact person (for legal entities)</u>
Novartis AG	Lichtstrasse 35, 4056 Basel, Switzerland	41613245365	marc.ceulemans@novartis	Marc Ceulemans

The personal data which you have provided to the FSMA via this form will be processed by the FSMA as set out in its [Privacy Policy](#).